[Endocrinal and chemotherapy of the metastasising mastocarcinoma (author's transl)]

Treatment of the metastasising mastocarcinoma is based on endocrinal and cytostatic treatment methods arranged systematically in parallel and in series. With endocrinal therapy alone, remission rates of around 30% are achieved, whereas with polychemotherapy the remission rates are 50 to 60%. For a large proportion of the patients, the systematic application of both methods leads to definite increase in life expectancy at a tolerable quality of life level. The determination of steroid hormone receptors in the tumorous tissue allows better selection of the patients and hence better on-target therapy.